Tempus AI is trading higher Friday as traders digest the latest follow-through from this week’s Merck–Moderna clinical-trial headline.

Tempus AI (TEM) trades higher after positive Phase 3 mRNA cancer trial results spotlight its $1.5B acquisition of Personalis.

Tempus AI is trading higher Friday as traders digest the latest follow-through from this week’s Merck–Moderna clinical-trial headline.